Robert Wild Email & Phone Number

California, United States

Ganymede Oncology is a precision medicine company revolutionizing cancer treatment through targeted modulation of the Nrf2 pathway. This pathway, a key regulator of cellular defense against oxidative stress and toxins, plays a dual role. While Nrf2 activation protects normal cells, it can also be exploited by cancer cells to promote growth and resist therapies. Mutations, overexpression, or misregulation of Nrf2 or its negative regulators—Keap1 and CUL3—are prevalent in many cancers, including up to 25% of non-small cell lung cancers, 20% of head and neck cancers, and 10% of liver cancers.Ganymede’s innovative approach focuses on precision therapies that selectively target Nrf2. Our strategy includes developing compounds that either directly target Nrf2 or indirectly inhibit its upstream mediators. By leveraging advanced technologies like structure-based drug design, genomics, proteomics, and bioinformatics, we aim to identify targeted therapeutics and biomarkers for personalized patient care. With a team of leading scientists, drug developers, and advisors, Ganymede Oncology is at the forefront of transforming cancer treatment. Our commitment to innovation and personalized care drives us to offer hope and better outcomes to patients worldwide.

Azkarra Therapeutics (www.azkarrabio.com) is an emerging precision therapeutics company, focused on the development of next generation DNA Damage Response (DDR)-modulating oral small molecule therapeutics for cancer and inflammatory diseases. The company was founded by Alan Ashworth, PhD, a world-renowned key opinion leader in translational science of cancer genetics. One of Dr. Ashworth’s key scientific contributions has been the discovery of BRCA2 and the elucidation of the synthetic lethal relationship between BRCA1 and BRCA2 mutations and Poly ADP ribose polymerase (PARP) inhibition. These discoveries paved the way for a new cancer treatment paradigm in multiple solid tumors and ushered in a multi-billion-dollar PARP inhibitor market. At Azkarra Therapeutics we aim to exploit molecular targets at the intersection of DDR and immune response and develop novel therapeutics for cancer and inflammatory diseases. We have identified a portfolio of promising next generation DDR-therapeutics, encompassing a well-differentiated, best-in-class multi-PARP inhibitor for DDR dependent cancers, a first-in-class OGG-1 inhibitor for inflammatory diseases/fibrosis and cancer as well as a best-in-class PARG inhibitor for cancer. As acting CEO, I oversaw the operations and advancement of the entire R&D portfolio and led all fund raising as well as business development activities.

New York, Us

Dracen Pharmaceuticals is a private biotech company developing novel oncologydrugs in the field of immuno-metabolism. As Chief Scientific Officer, my responsibilities included setting and executing the overarching R&D strategy and managing all drug discovery (biology and chemistry), preclinical development, CMC and translational research activities leading to the identification/selection and clinical development of Dracen’s first-in-class glutamine antagonist DRP-104 (sirpiglenastat) currently in phase 2a clinical trials. I also functioned as the scientific executive leader in fund raising and business development activities to support corporate objectives.

• Led strategic consulting services for biotech and pharmaceutical clients, specializing in oncology drug discovery and development.• Provided expertise in asset assessment, target identification, drug discovery strategy, biomarker strategy, and clinical development.• Successfully guided clients in corporate strategy, portfolio prioritization, and fundraising efforts.

South San Francisco, California, Us

Pandect Bioventures is a new venture firm focusing on investing in transformational healthcare ideas at the earliest stage, then leverage the knowledge and resources of our rich ecosystem to help build these ideas into successful life science companies. Pandect Bioventures provides Series A and later funding to early-stage biotech and pharma companies, along with full management support to help entrepreneurs achieve critical business milestones. As one of the founding EIRs, I provide scientific and strategic advice on new and existing investment opportunities and portfolio companies.

South San Francisco, Ca, Us

ShangPharma Innovation is a global innovation incubator and investment organization focusedon biomedical R&D technologies and therapeutics. Collaborations include proof of conceptresearch at academic and major medical centers, research institutes, and seed-­stage start-­ups,leading to industry collaborations and venture capital financing. As one of four founding external EIRs, Dr. Wild is providing technical and strategic advice on investment opportunities as well as business development support for ShangPharma portfolio companies and partners.

Founded in 1985, Domain was one of the first venture capital firms to exclusively invest in the life sciences sector. Domain has been involved in the formation of more than 260 companies. Today,with more than $2.7 billion in capital raised, Domain is a proven healthcare venture capital leaderwith solid investment returns from companies built to advance human health. As one of Domain’sEIRs, Dr. Wild consulted on oncology investment opportunities and company creations.

Executive leader of Ignyta’s Research organization. Responsible for setting overarching research strategy and leading all drug discovery as well as translational research activities. Significantly contributed to shaping Ignyta’s development pipeline including advancement of lead asset entrectinib from phase 1 early clinical development into a tumor agnostic registration enabling phase 2 study. Helped to transform Ignyta's pipeline via strategic asset identification and successful acquisition of 5 differentiated NMEs. Built internal drug discovery organization and portfolio prioritization process. Scientific representative for Ignyta (NASDAQ: RXDX) in regular investment/quarterly update calls with analysts and financial community. Scientific leader in fund raising activities.

Indianapolis, Indiana, Us

Scientific leader for oncology discovery and translational research efforts at Lilly corporateheadquarters in Indianapolis in the areas of cancer cell/oncogene signaling, cancer metabolism,developmental pathways and cell cycle control. Direct management responsibility for a team of>100 FTEs and contractors. Team successfully advanced 5 programs to IND (3 small molecules, 2 biologics), >15 programs to full discovery, and >40 programs to early discovery. Effectively supported >10 programs during various stages of clinical development with biomarker and translational research expertise.

Head of the Departments of In Vivo Pharmacology, Veterinary Sciences, Molecular Imaging &Research DMPK and member of the Oncology Research Leadership Team (ORLT) and Translational ResearchLeadership Committee (TLC) with shared responsibility for setting strategy and the day-to-day management of the oncology discovery & translational research portfolio at OSI.

Lawrence Township, Nj, Us

Lead in vivo pharmacology representative and project leader on multiple oncology projectteams. Projects involved early phase to full and post-IND stage programs and included signaltransduction targets, anti-mitotic targets, apoptosis pathway targets, cytotoxic agents as well asbiologics. Significant responsibility for project management including the design andimplementation of all in vivo tumor model testing strategies leading to successful projecttransitions and identification of new clinical drug candidates.

Pharmacologist on the Sutent® (sunitinib) preclinical drug discovery team at SUGEN. Developedand characterized several target driven in vitro and in vivo oncology disease models (AML,CML, MM, RCC) for lead selection, proof of concept and translational research purposes.

Ph.D., Pharmacology

B.S., Biochemistry

Abitur, Biology, Chemistry, Economics, English

Pharmaceutical Management